|Former Common name||BALB/c/Pas-Relnrl/+|
|H-2 Haplotype||No Data|
|Strain description||No Data|
|Health Report||No Data|
|Common name||No Data|
|Symbol description||No Data|
|Research applications||No Data|
|Specific Term and Conditions||The following terms and conditions will be requested by the DEPOSITOR.
The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR.
* The RIKEN BRC shall maintain, store, multiply and distribute the BIOLOGICAL RESOURCE in Japan only.
* Before any access to the biological resource, the Recipient will sign (as well as his/her administrative authority) the enclosed form to be sent to the Depositor (Institute Pasteur).
* Prior to applications for a patent, or intellectual property or other rights based on the results of research using the BIOLOGICAL RESOURCE, the recipient shall discuss such applications with the DEPOSITOR. Use of the BIOLOGICAL RESOURCE shall be a collaborative research with the DEPOSITOR. The DEPOSITOR requires to be co-owner for the inventions or other intellectual property generated by using the BIOLOGICAL RESOURCE.
|2||Genotyping protocol <PCR>|
|Depositor||Guenet, Jean-Louis (Institut Pasteur)|
|Strain Status /
|Genetic and animal model analyses reveal the pathogenic role of a novel deletion of RELN in schizophrenia.||Sci. Rep.13046 (2018).(30158644)|
|Akira Sobue, Itaru Kushima, Taku Nagai, Wei Shan, Takao Kohno, Branko Aleksic, Yuki Aoyama, Daisuke Mori, Yuko Arioka, Naoko Kawano, Maeri Yamamoto, Mitsuharu Hattori, Toshitaka Nabeshima, Kiyofumi Yamada & Norio Ozaki.|